Transcription
PRESS KIT
PRESS KITTABLE OF CONTENTSAbout the DIA 2022 Global Annual Meeting.3DIA Leadership. 4Keynote Speakers. 5Honorary Chairs. 6Key Tracks.7DIAmond Sessions. 9Schedule At-A-Glance.10“Patients Included” Event. 11DIA Social Growth since 2019. 12DIAglobal.org2
PRESS KITABOUT THE DIA 2022 GLOBAL ANNUAL MEETINGDIA, founded as the Drug Information Association, has provided a neutral and transparent global collaboration dedicated to addressinghealthcare challenges for over 50 years. DIA’s Global Annual Meeting (DIA 2022) gathers stakeholders from across the world to openlyshare knowledge and generate insights beyond boundaries to advance innovation in healthcare product development and lifecyclemanagement for all regions.Everyone passionate about working toward aligning the global intersection of science, healthcare, and regulation come together in theDIA community. Our organization and members represent no barriers, simply free-flowing dialogue between thought leaders, regulators,and professionals who may not otherwise connect. As the largest, longest-running event in the life sciences industry, DIA 2022 is designedto foster the international exchange of successful and actionable insights to improve healthcare accessibility through the advancement oflifesaving medicines and technologies.The DIA 2022 Global Annual Meeting will host thousands of professionals in the pharmaceutical, biotechnology, and medical devicecommunities from more than 50 countries around the globe, as well as hundreds of exhibiting companies. The goal of the DIA GlobalAnnual Meeting is to provide you and your team with a rare opportunity to build on what you already know in the development of newtherapies and accelerate efforts to enhance health and well-being for all.DIAglobal.org3
PRESS KITDIA LEADERSHIPExecutive Leadership Team Barbara Lopez Kunz, MS – Global Chief Executive Officer Jack Foster – Chief Financial Officer Timothy Hess – Vice President of IT Katie Hill – Vice President of Learning and Digital Solutions Anna McDermott-Vitak – Interim Senior Vice President &Managing Director, DIA Americas Ania Mitan – Senior Vice President & Managing Director, DIAEMEA, India and Singapore Hajime Saijo – Senior Vice President & Managing Director,DIA Japan Tong-Yan Wang – Senior Vice President & ManagingDirector, DIA ChinaBoard of Directors Judith Ng-Cashin – Chair of DIA Board and Chair ofExecutive Committee Lingshi Tan – Immediate Past Chair and Chair of GovernanceCommittee Cynthia L. Verst – Chair-Elect and President, Design andDelivery Innovation of Research & Development Solutions atIQVIA Michael Romano – Secretary/Treasurer and Chair of FinanceCommittee and Partner in RRSM’s Managed TechnologyServices Practice Barbara Lopez Kunz, MS – President and Global ChiefExecutive Officer of DIA Mike A. B. Devoy, MB, BS – DIA Director and Executive VicePresident for Medical Affairs and Pharmacovigilance for thePharmaceuticals Division at Bayer AG Elizabeth Garner, MD, MPH – DIA Director and Expert inPharmaceutical Development Peter Honig, BA, MD, MPH – DIA Director and former SVPand Head of Global Regulatory Affairs and Group Head ofDevelopment for China and Japan at Pfizer Frank N. Jiang, MD, PhD – DIA Director and ChiefExecutive Officer and Chairman of the Board of CStonePharmaceuticals Tatyana Kosheleva, CPA – DIA Director, Chair of AuditCommittee, and CFO/Executive Board Member at AmringPharmaceuticals Inc. Michael Rosenblatt, MD – DIA Director and Senior Partner atFlagship Pioneering Peter Sorger, AB, PhD – DIA Director and Otto KrayerProfessor of Systems Pharmacology at Harvard MedicalSchool Kihito Takahashi, PhD – DIA Director and Director and ChiefOperating Officer of bio-tech venture BONAC Corporationin Japan Karin Van Baelen – DIA Director and head of the GlobalRegulatory Affairs organization at Janssen Rachel Zhang – DIA Observer with two decades ofHealthcare Consulting and Life Science ManagementexperienceAdvisory Councils Gerald J. Dal Pan, MD – Chair, Council of Regulators LiaisonCommittee, US Food and Drug Administration Liaison to theDIA Board Peter Bachmann, PhD – Council of Regulators LiaisonCommittee, European Regulatory Network Liaison to theDIA Board Yoshiaki Uyama, PhD – Council of Regulators LiaisonCommittee, Japan Pharmaceuticals and Medical DevicesAgency Liaison to the DIA Board Catherine Parker – Council of Regulators, Health CanadaLiaison to the DIA Board Mike Ward – Council of Regulators, World HealthOrganization Liaison to the DIA BoardDIAglobal.org Yee Hoo Looi, PhD – Council of Regulators, Health SciencesAuthority Singapore Liaison to the DIA Board Nam-Hee Lee, PhD – Council of Regulators, Ministry of Foodand Drug Safety Liaison to the DIA Board Craig Lipset, MBA – Chair, Regional Advisory Council,Americas Jingsong Wand, MD – Chair, Regional Advisory Council,China Maren von Fritschen, PhD – Chair, Regional AdvisoryCouncil, EMEA Kazumichi Kobayashi, RPh – Chair, Regional AdvisoryCouncil, Japan4
PRESS KITKEYNOTE SPEAKERS ON THE FUTURE OF HEALTHCAREKen GetzDirector Center for the Study of Drug Development at Tufts UniversityPatients have always been at the center of their care but there is growing need and acceptance in clinicalR&D that patients are stakeholders in clinical decision making, health IT user experience, and medical productdevelopment. Focusing on what matters to patients and gathering feedback through the clinical developmentpipeline is an important element of improving study quality and ultimately impacting accessibility, perceptions,and market penetration. Patient preferences and satisfaction also serve as indicators for continuous improvementthat can drive retention and operational efficiency.Miruna SasuPresident and Chief Executive Officer, COTAThe COVID-19 pandemic has brought increased awareness to the importance of including the intended populationfor use of products in their development. Specifically, assuring gender, racial and ethnic, and age-related diversityand inclusion are actively sought and included in the design, testing and implementation of approaches for thetreatment and prevention of disease. This presentation will focus on the use of data and analytics, includingartificial intelligence to recruit a representative population for a trial.Emer CookeChair International Coalition of Medicines Regulatory Authorities (ICMRA)Overcoming barriers to access globally requires information sharing, trusted communication, and increasedawareness of regulatory science challenges. Collaboration and coordination, as demonstrated by medicinesregulatory authorities in times of crisis, can enhance global reliance and cooperation to increase efficiency andbring solutions to the patients that need them.Andre AsburyManager, Chicago Lighthouse Tools for Living Retail StoreDigital technologies such as wearables and video-enabled exchanges now allow for the remote collection of dataand interactions with patients. In this talk a patient will share first-hand accounts of the impact of digital access totheir health journey and participation in clinical trials.DIAglobal.org5
PRESS KITHONORARY CHAIRSStephanie Y. Crawford, PhD, MPHProfessor, UIC College of Pharmacy - Pharmacy Systems Outcomes and PolicyStephanie Y. Crawford, PhD, MPH, FAPhA, is a pharmacist, educator, researcher, and public health advocate. She isExecutive Associate Dean for Faculty Affairs & Strategic Initiatives and professor in the Department of PharmacySystems, Outcomes and Policy at the University of Illinois at Chicago (UIC) College of Pharmacy. She holds a jointappointment as professor in the Department of Medical Education, UIC College of Medicine and is an affiliatefaculty member in the UIC Center for Pharmacoepidemiology and Pharmacoeconomic Research. Since 2015, shehas chaired the United States Pharmacopeia Expert Committee on Nomenclature and Labeling, which establishes the official title of alldrug products in the U.S. She was a charter member of the U.S. Food and Drug Administration Advisory Committee on Drug Safety andRisk Management (DSaRM) and has continued to serve as a consultant and ad hoc voting member for the DSaRM since 2003. She chairsthe Regional Advisory Council for the Americas for DIA. In December 2020, she was appointed as a member of the Chicago Department ofPublic Health COVID-19 Vaccine Scientific Advisory Committee.Robert M. Califf, MDCommissioner of Food and Drugs at FDADr. Robert M. Califf was confirmed earlier this year as the 25th Commissioner of Food and Drugs.As Commissioner, Dr. Califf oversees the full breadth of the FDA portfolio and execution of the Federal Food,Drug, and Cosmetic Act and other applicable laws. This includes assuring the safety, effectiveness, and securityof human and veterinary drugs, vaccines and other biological products for human use, and medical devices;the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation; and theregulation of tobacco products.Dr. Califf has had a long and distinguished career as a physician, researcher, and leader in the fields of science and medicine. He is anationally recognized expert in cardiovascular medicine, health outcomes research, health care quality, and clinical research, and a leader inthe growing field of translational research, which is key to ensuring that advances in science translate into medical care.This is Dr. Califf’s second stint as Commissioner. He also served in 2016 as the 22nd Commissioner. Before assuming the position at thattime, he served as the FDA’s Deputy Commissioner for Medical Products and Tobacco.Prior to rejoining the FDA in 2022, Dr. Califf was head of medical strategy and Senior Advisor at Alphabet Inc., contributing to strategy andpolicy for its health subsidiaries Verily Life Sciences and Google Health. He joined Alphabet in 2019, after serving as a professor of medicineand vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational MedicineInstitute and was the founding director of the Duke Clinical Research Institute.Dr. Califf is a graduate of Duke University School of Medicine. He completed a residency in internal medicine at the University of California,San Francisco and a fellowship in cardiology at Duke.DIAglobal.org6
PRESS KITKEY TRACKSTRACK1TRACK2TRACK3TRACK4TRACK5TRACK6Clinical Safety and Pharmacovigilance This track provides an overview of the global regulatory environment in the field of clinical safety and pharmacovigilance formedical products (biopharmaceutical products, advanced therapies, and medical devices), with a focus on pragmatic approaches toprotecting patient safety and incorporating the patient voice into the complex and evolving pharmacovigilance ecosystem. Forwardthinking sessions address the application of new technologies and methods to streamline pharmacovigilance systems and processesto enhance protection of patient safety as products become more complex, new data sources drive new analytical techniques,regulatory requirements become more detailed, and medical product development becomes more global.Clinical Trials and Clinical Operations This comprehensive track covers the latest advances in clinical research and operations. Sessions cover innovative design strategies,establishing efficiencies in operations, and effective integration of patient outcomes in clinical trial design. Stakeholders will alsodiscuss new and ongoing challenges related to clinical trial coordination and outcomes, data management, patient safety, andcollaborate on actionable solutions for all those impacted by this vast field.Data and Technology in Clinical Trials Innovative technologies are improving efficiency in the collection of data from clinical trials. This track focuses on recentdevelopments in clinical data curation, which includes the structure, organization, validation, storage, extraction, and delivery ofdiverse types of patient data to facilitate review, analysis, and reporting in regulatory submissions. Specifically, the track will have thefollowing as focal points: Structured and unstructured data sources Blockchain technology and cloud computing Data Quality and Standards Real World Data / Evidence Mobile / wearable technologies Informatic solutions and machine learning Evolving data requirements to support new endpointsMedical Affairs and Scientific Communication This track will share global insights from medical affairs professionals and medical writers. Sessions will address necessary skills andbest practices for compliance in an increasingly cross-functional work environment for the medical affairs, medical information, andscientific communication professional.Patient Engagement Address meaningful patient engagement in medical product development, from early product development, and approval, throughmaintenance phases. This track focuses on important questions for all stakeholders, including; How do we meaningfully engage the patient voice in decision-making throughout the medical product lifecycle? How do we operationalize patient-centric approaches in our day-to-day work? How can we measure the effectiveness of our efforts, both for patient outcomes and to meet the needs of other stakeholderssuch as industry and regulatory decision-makers? What have we learned that can be used to drive more meaningful patient engagement? How do stakeholders best leverage their collective power and expertise to promote meaningful involvement of patients?Preclinical Development and Early-Phase Clinical Research Preclinical and early-phase clinical research provides initial dosing and safety data for new drugs. This track focuses on the lateststrategies used in early-stage compound selection, updates on safety considerations for both drugs and biologics, how PK/PDaffects dosing strategies, and methods to improve data quality and integrity for proper downstream decision-making.DIAglobal.org7
PRESS KITTRACK7Project Management and Strategic Planning Examine best practices to improve project and program execution, strategic planning, and portfolio management. Sessions willhighlight how to collaborate more effectively with internal and external stakeholders to achieve optimal efficiencies in project andprogram development.R&D Quality and Compliance TRACK8TRACK9TRACK10TRACK11TRACK12Gain a comprehensive view of the quality landscape across the preclinical, clinical, and pharmacovigilance domains within thebiopharmaceutical industry. Sessions are focused on discussing innovative and risk-proportionate approaches to managing qualitythat are appropriate to an evolving development paradigm and in a global context. Sessions will address key topics in GLP, GCP, andPV quality, providing knowledge and resources needed to implement pragmatic, proactive, and effective quality management.Regulatory Sessions address global laws, regulations, guidelines, and guidances that govern prescription biopharmaceutical and device productdevelopment, approval, and maintenance. Representatives from FDA, Health Canada. NMPA, PMDA, EMA, MHRA, European HealthAuthorities and ICMRA authorities, and other regulatory experts will provide global updates, insights, and discussion on currentissues through interactive forums. Themes commonly revolve around Global Regulatory Changes and Impact on Global DevelopmentStrategies, Global Harmonization/Convergence and Impact on Drug Development and Advances and Innovations to Improve thePractice of Regulatory Affairs, and Regulatory Hot Topics are always prominently featured.Regulatory CMC and Product Quality Evaluate risk-based approaches across the product lifecycle. The track scope spans from the scientific understanding gained throughproduct and process development to lifecycle expectations for Global Regulatory CMC submissions, CGMP, and Quality Systems.Sessions address the increasing regulatory complexity of development and manufacturing for worldwide markets, accelerateddevelopment timelines, new technologies, emerging regulations, and increased scrutiny of manufacturing operations and data.Statistics Examine topics of practical and theoretical statistical interest for professionals who work with medical products, includingpharmaceuticals, biologics and biosimilars, combination products and devices, and generics throughout their lifecycle. Sessions willexplore topics related to current statistical thinking which inform policy, regulation, development, review, and lifecycle managementof medical products in the context of the current scientific and regulatory environments. A new aspect of the track is data science,a multidimensional area with the two major dimensions of curation and analysis. This track is focused on the analysis dimension,including analytics and predictive analytics.Value and Access The healthcare landscape is evolving into one assessed on value, and there is a need to understand the impact of this movementon all stakeholders – providers, payers, biopharma, and ultimately patients. Value and access to medicines are complex issuesthat require analysis from health economic and philosophical perspectives. The Value and Access track will bring together globalregulators, industry leaders, academics, patients, and payers who will facilitate discussions and address questions such as: What information and evidence are being used to define value? How can bioethics be used to improve the drug development process? How can real-world data be leveraged to drive access to medicines? What are the regulatory and legal considerations surrounding value-based contracting conversations with payers?Professional Development TRACK13These topics focus on how to improve and support ongoing personal growth for career and team success. This broad categoryincludes interpersonal skills, soft skills, leadership, goal setting, life-long learning, career transitions (career growth, lateral careertransitions, and entrepreneurship), social media/new media, and self-awareness to assess strengths, knowledge gaps, and room forgrowth.DIAglobal.org8
PRESS KITDIAMOND SESSIONSOur DIAmond sessions provide you with rare opportunities to listen to and engage with a variety of key stakeholdersparticipating in open conversations on controversial topics such as the opioid crisis, the future of PharmaTech, globalperspectives on patient engagement, international regulatory convergence, and a forum with the FDA.TUESDAYJUNE21Preparing for the Future of Research and Development: 10-Years of MultistakeholderInnovation, Collaboration, and Transformation11:00AM CDTChair: Barbara Lopez Kunz, Global Chief Executive Officer, DIA, United StatesThis forum will feature a panel of Industry leaders at the top of their field candidly discussing why collaboration in the R&Decosystem is an important force and plays a key role in shaping the future of healthcare and bridging the gap betweenclinical research and clinical care. Knowledge-share on the industry response to COVID-19, impacts of technology on drugdevelopment, and factors influencing the future of clinical trials. Find your collaborative role in the innovative future of R&D.WEDNESDAYJUNE22Leveraging Real-World Evidence to Address Diversity Gaps in Randomized Clinical Trials:Regulatory, Clinical, and Other Considerations11:00AM CDTChair: Nancy A. Dreyer, PhD, MPH, FISPE, Chief Scientific Officer & SVP, IQVIA, United StatesIf randomized clinical trials (RCTs) are enlarged to address treatment benefits and risks in subgroups of interest, they willtake longer to complete. This forum considers regulatory, clinical and pharma use of real-world evidence to supplementRCT to address diversity. This forum will be a lively panel discussion with perspectives from the regulatory, clinical, andbiopharmaceutical perspective, focusing on best ways to fill these evidence gaps including use of real-world evidence. Learntrade-offs between running larger more diverse clinical trials and time to trial completion and product approval. Explorehow the lack of diversity in clinical trials impacts the reliability of evidence-based care algorithms. Consider how real-worldevidence can contribute to understanding diversity and how that would extend what is learned from trials.THURSDAYJUNE23EMA-FDA Question Time10:00AM CDTChairs: Anabela Marcal, PharmD, EMA Liaison Official to the US FDA, European Medicines Agency, NetherlandsKatherine Tyner, PhD, FDA Liaison to the EMA, Office of Global Policy and Strategy, OC, FDA, United StatesIn this interactive session, experts from EMA and FDA will address questions from the audience and share their experiences ofcollaboration in specific areas, including regulatory and scientific challenges and lessons learned in a COVID-19 environment.In this session you will: analyze the regulatory and scientific collaboration between EMA and FDA; explore specific areas ofcollaboration between these two agencies; describe how EMA and FDA addressed regulatory and scientific challenges in aCOVID-19 environment and discuss lessons learned.FDA Town Hall11:30AM CDTChair: Courtney Granville, PhD, MPH, Global Associate Director, Research and Scientific Programs, DIA, United StatesThis forum will include discussions and updates from FDA leadership on regulatory issues and the audience will be invited tosubmit questions of general interest. Discuss regulatory issues and updates to include hot topics.DIAglobal.org9
Schedule At-A-GlancePRESS KITDIAglobal.org/DIA2022As of 5/16/22. Schedule subject to change.All times are in Central Daylight Time (GMT-5).SCHEDULE AT-A-GLANCEMONDAY, JUNE 13-THURSDAY JUNE 1610:00-11:15AMPre-Conference Short Courses (Virtual)Coffee Break (Exhibit Hall)Innovation Theater Presentations (Exhibit Hall)11:00AM-12:15PMDIAmond Session and Educational Sessions12:00PM-1:30PMLuncheon Service (Exhibit Hall)Community Networking Area (Exhibit Hall)Professional and Student Poster Presentation12:30-1:30PMInnovation Theater Presentations (Exhibit Hall)Content HubsCommunity Roundtable Discussions1:45-3:00PMEducational Sessions2:45-4:30PMRefreshment Break (Exhibit Hall)Innovation Theater Presentations (Exhibit Hall)Content HubsCommunity Roundtable Discussions4:15-5:15PMEducational SessionsRegistration for Preconference Short Courses is open. Register NowSchedule9:30AM-12:30PMHalf-Day Morning Preconference Short Courses*1:00-4:00PMHalf-Day Afternoon Preconference Short Courses**Space is limited for Preconference Short Courses.SATURDAY, JUNE 18Registration Hours8:00AM-5:00PMExhibitor RegistrationSUNDAY, JUNE 19Registration HoursWEDNESDAY, JUNE 228:00AM-5:00PMExhibitor Registration1:00-5:00PMRegistration for Conference Attendeesand SpeakersRegistration Hours8:00AM-5:15PMAttendee, Speaker and Exhibitor Registration8:00-9:00AMCoffee ServiceMONDAY, JUNE 20Schedule6:30-7:45AM9:00-10:15AMEducational Sessions10:00AM-4:30PMExhibit Hall Open10:00-11:15AMCoffee Break (Exhibit Hall)Innovation Theater Presentations11:00AM-12:15PMDIAmond Session and Educational Sessions12:00PM-1:30PMLuncheon Service (Exhibit Hall)Community Networking Area (Exhibit Hall)Professional and Student Poster Session12:30-1:30PMInnovation Theater Presentations (Exhibit Hall)Content HubsCommunity Roundtable Discussions1:45-3:00PMEducational Sessions2:45-4:30PMRefreshment Break (Exhibit Hall)Innovation Theater Presentations (Exhibit Hall)Content HubsCommunity Roundtable Discussions4:15-5:15PMEducational SessionsCISCRP Medical Heroes Appreciation 5KWalk & RunRegistration Hours8:00AM-6:00PMAttendee, Speaker, and Exhibitor RegistrationSchedule8:00-10:00AMCoffee Service9:00-9:45AMAnnual Meeting Orientation9:00AM-4:30PMPoster Session 1 Viewing Hours10:00-11:30AMOpening Plenary, Keynote Address, andDIAmond Session11:00AM-6:00PMExhibit Hall Open11:30-1:00PMLuncheon Service (Exhibit Hall)Community Networking Area (Exhibit Hall)12:00-1:15PMProfessional and Student Posters PresentationInnovation Theater Presentations (Exhibit Hall)Content HubsCommunity Roundtable Discussions1:15-2:30PMEducational Sessions2:15-4:00PMRefreshment Break (Exhibit Hall)Innovation Theater Presentations (Exhibit Hall)Content HubsCommunity Roundtable Discussions4:00-5:00PMEducational Sessions5:00-6:00PMExhibit Hall ReceptionTUESDAY, JUNE 21Registration Hours8:00AM-5:15PMAttendee, Speaker, and Exhibitor Registration8:00-9:00AMCoffee ServiceSchedule9:00-10:15AMEducational Sessions9:00AM-4:30PMPoster Session 2 Viewing Hours10:00AM-5:00PMExhibit Hall OpenDIAglobal.orgTHURSDAY, JUNE 23Registration Hours8:00-11:00AMAttendee and Speaker Registration8:00-9:00AMCoffee ServiceSchedule9:00-9:45AMContent HubsCommunity Roundtable Discussions10:00-11:00AMDIAmond Session and Educational Sessions11:00-11:30AMCoffee Break11:30AM-12:30PMFDA Town HallTHANK YOU TO OUR MEDIA PARTNERS:10
PRESS KITDIA 2022 IS DESIGNATED AS A “PATIENTS INCLUDED” EVENTDIA 2022 is a “Patients Included” event, which means that we are committed to incorporatingthe experience of patients as experts in living with their condition while ensuring they are neitherexcluded nor exploited. For more information, visit the Patients Included website.DIA and the Global Annual Meeting Program Committee have assessed that the programsuccessfully meets all five of the Patients Included charter clauses:Patients or caregivers with experience relevant to the meeting’s central theme actively participatein the design and planning of the event, including the selection of themes, topics, and speakers. The DIA 2022 program agenda has been structured to incorporate the patient perspectivewithin a dedicated Patient Engagement Track. The Program Committee includes patientrepresentatives, who have responsibility for building the Patient Engagement track, advising onappropriate inclusion of patient perspectives in sessions throughout all 13 educational tracks, andserving as resources to identify qualified patient speakers As speakers, patients invited to speak in sessions will receive complimentary registration DIA facilitates the attendance of patients or patient partners at the DIA 2022 Global Annual Meeting through the Patient ScholarsProgram. Registration scholarships are available for the DIA 2022 meeting. DIA offers a special registration fee for patients and patient organization representatives of 250 if registered by May 31. After May 31,the standard patient registration rate of 400 will apply. Access the Patient Registration FormPatients or caregivers with experience of the issues addressed by the event participate in its delivery, and appear in its physicalaudience. Patients and patient partners with experience or interest in furthering the impact of their involvement in medical product developmentare featured as speakers, panelists, and discussants throughout the program The Patient Partners Speaker Initiative assists the Program Committee and session developers with finding the right patient/patientpartner to speak in the programThe disability requirements of participants are accommodated. All applicable sessions, breakouts, ancillary meetings, and otherprogram elements are open to patient delegates. DIA 2022 will be held at McCormick Place West, 2301 South Indiana Avenue, Chicago, Illinois 60616. The facility features accessibleentrances, registration and open areas, meeting rooms, parking, and provides assistive devices. In addition to McCormick Place, DIA hasreserved sleeping room blocks at special conference rates in hotels surrounding the convention center. A complete list of hotels can beviewed here. For specific questions, please contact the hotel directlyAccess for virtual participants is facilitated, with free streaming video provided online wherever possible. The hashtag #DIA2022 will be actively promoted prior to and during the event across social media platforms so participants, as well asthose unable to attend the event, can join the conversation and discuss presentations and key takeaways DIA will post speaker presentations to the DIA website prior to the meeting and for six months after the meeting for viewing anddownloading by attendees DIA is caputuring educational sessions for on-demand viewing. Access to recorded content will be available for two months after themeeting for viewing by patient attendees.DIAglobal.org11
PRESS KITDIA 2021 GLOBAL ANNUAL MEETING VIRTUAL-ONLY ATTENDANCE STATS14Hot TopicsSpeakersCountriesDIAmond SessionsSessions6922551961,000 Companies707Exhibitor Attendees25AgenciesDIA COMMUNITY EXPANSION THROUGH SOCIAL FOLLOWINGLinkedIn FacebookTwitter Followers Gained!2019: 16,2962019: 9,2012019: 12,9862022:
PRES I DIAglobal.org 4 Executive Leadership Team Barbara Lopez Kunz, MS - Global Chief Executive Officer Jack Foster - Chief Financial Officer Timothy Hess - Vice President of IT Katie Hill - Vice President of Learning and Digital Solutions Anna McDermott-Vitak - Interim Senior Vice President & Managing Director, DIA Americas .
